NJ drugmaker scores big profits off of cancer drugs in recent quarter: report

KENILWORTH-- Pharmaceutical giant Merck reported a 21 percent jump in fourth-quarter profits fueled partly by the rising sales of drugs for cancer and hepatitis C, News 4 New York reported Friday. Along with sales of Ketyruda and the hepatitis treatment Zepatier, company officials also attributed increased profits to an aggressive round of cost-cutting. Ketyruda, which was…